Targeted therapy of pancreatic cancer
- VernacularTitle:胰腺癌的靶向治疗
- Author:
Zhaoyan WANG
;
Erbing WANG
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Targeted therapy;
Gemcitabine;
Erlotinib
- From:
Cancer Research and Clinic
2008;20(7):433-435
- CountryChina
- Language:Chinese
-
Abstract:
Unresectable or metastatic pancreatic cancer carries a poor prognosis,and systemic therapy with cytotoxic agents provides marginal benefit. Even the first-line chemotherapeutic agent, gemcitabine(GEM) has a modest survival benefit,and objective tumor response is rarely achieved. Combination of various cytotoxics did not produce a significant improvement either. For that reason,continuous search for better molecules targeted agents and/or combinations is inevitable. Erlotinib, an orally bioavailable small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase, is the first of these targeted which compounds to be approved for use in combination with gemcimbine for patients with advanced pancreatic cancer. GEM with other targeted agents,including monoclonal antibodies: cetuximab or bevacizumab,also has been extensively evaluated,with limited success to date. Future research should continue to unravel the mechanism of pancreatic carcinogenesis and to identify key relevant molecular targets for therapeutic intervention.
